Company news

Nurix Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

March 16, 2025

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

March 12, 2025

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 3, 2025

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

January 27, 2025

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

January 21, 2025

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

January 12, 2025

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

December 18, 2024

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

December 8, 2024

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

December 1, 2024

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

November 24, 2024

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

November 19, 2024

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

November 16, 2024

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

November 4, 2024

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

October 20, 2024

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

October 18, 2024

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

October 15, 2024

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

October 10, 2024

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

October 8, 2024

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

September 29, 2024

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

September 5, 2024

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

July 10, 2024

Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day

July 7, 2024

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

June 15, 2024

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

June 9, 2024

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2024

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

May 27, 2024

Nurix Therapeutics Announces Board Chair Transition

May 19, 2024

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

May 13, 2024

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

May 6, 2024

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 15, 2024

Nurix Therapeutics Announces Proposed Public Offering

April 10, 2024

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

April 10, 2024

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

April 9, 2024

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

April 8, 2024

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

April 8, 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences

April 2, 2024

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

April 1, 2024

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

March 24, 2024

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

March 19, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

March 10, 2024

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

March 4, 2024

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

February 14, 2024

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

January 31, 2024

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL

January 15, 2024

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

January 7, 2024

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

December 10, 2023

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

December 3, 2023

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

November 1, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 32 decks. Every deck is listed under its year.